Silencing of CDK5 as potential therapy for Alzheimer's disease

Reviews in the Neurosciences

Volumn 22, Issue 2, 2011, Pages 143-152

  López Tobón, Alejandro ^a   Castro Álvarez, John Fredy ^a   Piedrahita, Diego ^a   Boudreau, Ryan L ^b   Gallego Gómez, Juan Carlos ^a   Cardona Gómez, Gloria Patricia ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Alzheimer's disease; cyclin dependent kinase 5 (CDK5); gene therapy; neurodegeneration; RNA interference; tauopathy

Indexed keywords

ALOISINE; BUTYROLACTONE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; HYMENIALDISINE; INDIRUBIN; LITHIUM; OLOMOUCINE; PAULLONE DERIVATIVE; PURVALANOL; ROSCOVITINE; TAU PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; ENZYME ACTIVITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; HUMAN; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SYNAPSE;

ALZHEIMER DISEASE; ANIMALS; CYCLIN-DEPENDENT KINASE 5; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; RNA INTERFERENCE;

EID: 79954580589     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/RNS.2011.015     Document Type: Article

References (102)

1. Alves, S., NascimentoFerreira, I., Auregan, G., Hassig, R., Dufour, N., Brouillet, E., Pedroso de Lima, M.C., Hantraye, P., Pereira de Almeida, L., and Deglon, N. (2008). Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3, e3341.
2. Angelo, M., Plattner, F., Irvine, E.E., and Giese, K.P (2003). Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 18, 423-431. (Pubitemid 36999943)
3. Angelo, M., Plattner, F., and Giese, K.P (2006). Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem. 99, 353-370. (Pubitemid 44477194)
4. Aronoff, R. and Petersen, C.C. (2006). Controlled and localized genetic manipulation in the brain. J. Cell. Mol. Med. 10, 333-352. (Pubitemid 44870183)
5. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., and Hyman, B.T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
6. Augustinack, J.C., Schneider, A., Mandelkow, E.M., and Hyman, B.T. (2002). Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103, 26-35. (Pubitemid 36075309)
7. Avila, J. and Hernandez, F. (2007). GSK-3 inhibitors for Alzheimer's disease. Expert Rev. Neurother. 7, 1527-1533. (Pubitemid 350106832)
8. Avila, J., Lucas, JJ., Perez, M., and Hernandez, F. (2004). Role of tau protein in both physiological and pathological conditions. Physiol. Rev. 84, 361-384. (Pubitemid 38365487)
9. Avila, J., Wandosell, F., and Hernandez, F. (2010). Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev. Neurother. 10, 703-710.
10. Ballatore, C, Lee, V.M., and Trojanowski, J.Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672. (Pubitemid 47283144)
11. Boudreau, R.L. and Davidson, B.L. (2010). RNAi therapeutics for CNS disorders. Brain Res. 1338, 112-121.
12. Boudreau, R.L., McBride, J.L., Martins, I., Shen, S., Xing, Y., Carter, B J., and Davidson, B.L. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063.
13. Bu, B., Li, J., Davies, P., and Vincent, I. (2002). Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J. Neurosci. 22, 6515-6525. (Pubitemid 35386408)
14. Chae, T., Kwon, Y.T., Bronson, R., Dikkes, P., Li, E., and Tsai, L.H. (1997). Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality Neuron 18, 29-42. (Pubitemid 27053828)
15. Chergui, K., Svenningsson, P., and Greengard, P. (2004). Cyclindependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proc. Natl. Acad. Sci. USA 101, 2191-2196. (Pubitemid 38229037)
16. Cheung, Z.H. and Ip, N.Y. (2007). The roles of cyclin-dependent kinase 5 in dendrite and synapse development. Biotechnol. J. 2, 949-957. (Pubitemid 47377102)
17. Cheung, Z.H., Fu, A.K., and Ip, NY. (2006). Synaptic roles of Cdk5: implications in higher cognitive functions and neurodegenerative diseases. Neuron 50, 13-18.
18. Cheung, Z.H., Chin, W.H., Chen, Y, Ng, YP, and Ip, N.Y. (2007). Cdk5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons. PLoS Biol. 5, e63.
19. Ching, YP, Pang, A.S., Lam, W.H., Qi, R.Z., and Wang, J.H. (2002). Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor. J. Biol. Chem. 277, 15237-15240. (Pubitemid 34967783)
20. Davidson, B.L. and Breakefield, X.O. (2003). Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci. 4, 353-364. (Pubitemid 37280174)
21. Deglon, N, Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y, Pereira de Almeida, L., Zufferey, R., Trono, D., and Aebischer, P. (2000). Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther. 11, 179-190. (Pubitemid 30044050)
22. Dhavan, R. and Tsai, L.H. (2001). A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759. (Pubitemid 33679837)
23. Engmann, O. and Giese, K.P (2009). Crosstalk between Cdk5 and GSK3β: implications for Alzheimer's disease. Front. Mol. Neurosci. 2, 2.
24. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, CC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811. (Pubitemid 28099681)
25. Fischer, P.M. (2001). Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr. Opin. Drug Discov. Dev. 4, 623-634. (Pubitemid 32904859)
26. Fischer, A., Sananbenesi, F, Spiess, J., and Radulovic, J. (2003). Cdk5: a novel role in learning and memory. Neurosignals 12, 200-208. (Pubitemid 37548234)
27. Fu, A.K., Ip, F.C, Fu, W.Y, Cheung, J., Wang, J.H., Yung, W.H., and Ip, N.Y. (2005). Aberrant motor axon projection, acetylcholine receptor clustering, and neurotransmission in cyclindependent kinase 5 null mice. Proc. Natl. Acad. Sci. USA 102, 15224-15229. (Pubitemid 41513363)
28. Giese, K.P (2009). GSK-3: a key player in neurodegeneration and memory. IUBMB Life 61, 516-521.
29. Global Burden of Disease Communication (2003). Mental health World Health Organisation. Available at: http://www.who.int/mental-health/neurology/en/.
30. Grant, P., Sharma, P., and Pant, H.C. (2001). Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism. Eur. J. Biochem. 268, 1534-1546. (Pubitemid 32862685)
31. Grundke-Iqbal, I., Iqbal, K., Tung, YC, Quinlan, M., Wisniewski, H.M., and Binder, L.I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83, 4913-4917.
32. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P, Wulffraat, N, Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419. (Pubitemid 37296260)
33. Hanger, D.P, Anderton, B.H., and Noble, W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
34. Hashiguchi, M., Saito, T., Hisanaga, S., and Hashiguchi, T. (2002). Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J. Biol. Chem. 277, 44525-44530. (Pubitemid 36157887)
35. Hawasli, A.H., Benavides, D.R., Nguyen, C, Kansy, J.W., Hayashi, K, Chambon, P., Greengard, P., Powell, CM., Cooper, D.C., and Bibb, J.A. (2007). Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. 10, 880-886. (Pubitemid 47018172)
36. Hilton, GD., Stoica, B.A., Byrnes, KR., and Faden, A.I. (2008). Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J. Cereb. Blood Flow Metab. 28, 1845-1859.
37. Hu, S., Begum, A.N., Jones, M.R., Oh, M.S., Beech, W.K, Beech, B.H., Yang, F., Chen, P., Ubeda, OJ., Kim, PC, et al. (2009). GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol. Dis. 33, 193-206.
38. Illanes, O., Anderson, S., Niesman, M., Zwick, L., and Jessen, B.A. (2006). Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicol. Pathol. 34, 243-248.
39. Iqbal, K, Liu, F., Gong, CX., Alonso Adel, C, and Grundke-Iqbal, I. (2009). Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118, 53-69.
40. Kerokoski, P., Suuronen, T., Salminen, A., Soininen, H., and Pirttila, T. (2004). Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (cdk5) activator p35 in cultured rat hippocampal neurons. Neurosci. Lett. 368, 181-185. (Pubitemid 39194868)
41. Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209-216. (Pubitemid 37329584)
42. Knockaert, M., Greengard, P., and Meijer, L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23, 417-425. (Pubitemid 35247771)
43. Kwon, I. and Schaffer, D.V. (2008). Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm. Res. 25, 489-499.
44. Kwon, YT., Gupta, A., Zhou, Y, Nikolic, M., and Tsai, L.H. (2000). Regulation of N-cadherin-mediated adhesion by the p35-Cdk5 kinase. Curr. Biol. 10, 363-372. (Pubitemid 30213382)
45. Lagace, D.C, Benavides, D.R., Kansy, J.W., Mapelli, M., Greengard, P., Bibb, J.A., and Eisch, A.J. (2008). Cdk5 is essential for adult hippocampal neurogenesis. Proc. Natl. Acad. Sci. USA 105, 18567-18571.
46. Lai, K.O. and Ip, N.Y. (2009). Recent advances in understanding the roles of Cdk5 in synaptic plasticity. Biochim. Biophys. Acta 1792, 741-745.
47. Lee, K.Y., Clark, A.W., Rosales, J.L., Chapman, K., Fung, T., and Johnston, R.N. (1999). Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34, 21-29. (Pubitemid 29245996)
48. Leost, M., Schultz, C, Link, A., Wu, YZ., Biernat, J., Mandelkow, E.M., Bibb, J.A., Snyder, G.L., Greengard, P., Zaharevitz, D.W., et al. (2000). Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 267, 5983-5994.
49. Li, B.S., Sun, M.K., Zhang, L., Takahashi, S., Ma, W., Vinade, L., Kulkarni, A.B., Brady, R.O., and Pant, H.C. (2001). Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc. Natl. Acad. Sci. USA 98, 12742-12747. (Pubitemid 33020016)
50. Liu, F., Su, Y, Li, B., Zhou, Y, Ryder, J., Gonzalez-DeWhitt, P., May, P.C., and Ni, B. (2003). Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 547, 193-196. (Pubitemid 36829404)
51. Lopes, J.P, Oliveira, C.R., and Agostinho, P. (2007). Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-β and prion peptides: implications for Alzheimer's dis-ease and prion-related encephalopathies. Cell. Mol. Neurobiol. 27, 943-957.
52. Loy, R. and Tariot, PN. (2002). Neuroprotective properties of val-proate: potential benefit for AD and tauopathies. J. Mol. Neurosci. 19, 303-307. (Pubitemid 36051521)
53. Lu, L., Grimm, J.W., Shaham, Y, and Hope, B.T. (2003). Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self-administration in rats. J. Neurochem. 85, 1604-1613. (Pubitemid 36702572)
54. Malenka, R.C. and Bear, M.F. (2004). LTP and LTD: an embarrass-ment of riches. Neuron 44, 5-21.
55. Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M., Endicott, J., Vierfond, J.M., and Meijer, L. (2003). Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectiv-ity, and cellular effects. J. Med. Chem. 46, 222-236. (Pubitemid 36078142)
56. Monaco, E.A., 3rd, Beaman-Hall, CM., Mathur, A., and Vallano, M.L. (2004). Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem. Pharmacol. 67, 1947-1964. (Pubitemid 38591383)
57. Morabito, M.A., Sheng, M., and Tsai, L.H. (2004). Cyclin-dependent kinase 5 phosphorylates the N-terminal domain of the postsynap-tic density protein PSD-95 in neurons. J. Neurosci. 24, 865-876. (Pubitemid 38146597)
58. Morfini, G., Szebenyi, G, Brown, H., Pant, H.C., Pigino, G., DeBoer, S., Beffert, U, and Brady, S.T. (2004). A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motil-ity in neurons. EMBO J. 23, 2235-2245. (Pubitemid 38833233)
59. Morita, A., Yamashita, N., Sasaki, Y, Uchida, Y, Nakajima, O., Nakamura, F., Yagi, T., Taniguchi, M., Usui, H., Katoh-Semba, R., et al. (2006). Regulation of dendritic branching and spine maturation by semaphorin3A-Fyn signaling. J. Neurosci. 26, 2971-2980.
60. Nacharaju, P., Lewis, J., Easson, C, Yen, S., Hackett, J., Hutton, M., and Yen, S.H. (1999). Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett. 447, 195-199. (Pubitemid 29146084)
61. Nguyen, M.D., Lariviere, R.C., and Julien, J.P (2001). Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by per-ikaryal neurofilament inclusions. Neuron 30, 135-147. (Pubitemid 32441682)
62. Nguyen, C, Nishi, A., Kansy, J.W., Fernandez, J., Hayashi, K, Gillardon, F., Hemmings, H.C., Jr., Nairn, A.C., and Bibb, J.A. (2007). Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5. J. Biol. Chem. 282, 16511-16520. (Pubitemid 47100396)
63. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P, Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P, Akbari, Y, and LaFerla, F.M. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunc-tion. Neuron 39, 409-421. (Pubitemid 36937044)
64. Ohshima, T., Ward, J.M., Huh, C.G, Longenecker, G., Veeranna, Pant, HC, Brady, R.O., Martin, L.J., Kulkarni, A.B. (1996). Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. USA 93, 11173-11178. (Pubitemid 26333137)
65. Otth, C, Mendoza-Naranjo, A., Mujica, L., Zambrano, A., Concha, I.I., and Maccioni, R.B. (2003). Modulation of the JNK and p38 pathways by cdk5 protein kinase in a transgenic mouse model of Alzheimer's disease. Neuroreport 14, 2403-2409.
66. Patrick, G.N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., and Tsai, L.H. (1999). Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622. (Pubitemid 129516324)
67. Peterson, D.W., Ando, D.M., Taketa, D.A., Zhou, H., Dahlquist, F.W., and Lew, J. (2010). No difference in kinetics of tau or his-tone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro. Proc. Natl. Acad. Sci. USA 107, 2884-2889.
68. Pfeifer, A. and Verma, I.M. (2001). Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet. 2, 177-211. (Pubitemid 35265005)
69. Piedrahita, D., Hernández, I., López-Tobón, A., Fedorov, D., Obara, B., Manjunath, B.S., Boudreau, R.L., Davidson, B., LaFerla, F., Gallego-Gómez, J.C., Kosik, KS., and Cardona-Gómez, G.P. (2010). Silencing of CDK5 reduces neurofibril-lary tangles in transgenic Alzheimer mice. J. Neurosci. 30, 13966-13976.
70. Plattner, F., Angelo, M., and Giese, K.P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyper-phosphorylation. J. Biol. Chem. 281, 25457-25465. (Pubitemid 44401934)
71. Przedborski, S., Vila, M., and Jackson-Lewis, V. (2003). Neuro-degeneration: what is it and where are we? J. Clin. Invest. 111, 3-10.
72. Qi, Z., Tang, D., Zhu, X., Fujita, D.J., and Wang, J.H. (1998). Association of neurofilament proteins with neuronal Cdk5 acti-vator. J. Biol. Chem. 273, 2329-2335. (Pubitemid 28069287)
73. Ramiro-Ibanez, F., Trajkovic, D., and Jessen, B. (2005). Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol. Pathol. 33, 784-791.
74. Raoul, C, Barker, S.D., and Aebischer, P. (2006). Viral-based model-ling and correction of neurodegenerative diseases by RNA inter-ference. Gene Ther. 13, 487-495.
75. Rapoport, S.I. (1999). In vivo PET imaging and postmortem stud-ies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 249 (Suppl. 3), 46-55.
76. Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, J.C., Rougvie, A.E., Horvitz, H.R., and Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906. (Pubitemid 30130993)
77. Sananbenesi, F., Fischer, A., Wang, X., Schrick, C, Neve, R., Radulovic, J., and Tsai, L.H. (2007). A hippocampal Cdk5 path-way regulates extinction of contextual fear. Nat. Neurosci. 10, 1012-1019. (Pubitemid 47185210)
78. Santacruz, K., Lewis, J., Spires, T, Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005). Tau suppression in a neurodegen-erative mouse model improves memory function. Science 309, 476-481. (Pubitemid 40994688)
79. Schmidt, M., Glimm, H., Wissler, M., Hoffmann, G., Olsson, K., Sellers, S., Carbonaro, D., Tisdale, J.F., Leurs, C, Hanenberg, H., et al. (2003). Efficient characterization of retro-, lenti-, and foamy vector-transduced cell populations by high-accuracy insertion site sequencing. Ann. N. Y. Acad. Sci. 996, 112-121. (Pubitemid 36706593)
80. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208. (Pubitemid 37329583)
81. Sen, A., Thom, M., Martinian, L., Jacobs, T., Nikolic, M., and Sisodiya, S.M. (2006). Deregulation of cdk5 in hippocampal sclerosis. J. Neuropathol. Exp. Neurol. 65, 55-66.
82. Smith, P.D., Crocker, SJ., Jackson-Lewis, V., Jordan-Sciutto, K.L., Hayley, S., Mount, M.P, O'Hare, MJ., Callaghan, S., Slack, R.S., Przedborski, S., et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 100, 13650-13655. (Pubitemid 37444794)
83. Sultana, R. and Butterfield, D.A. (2007). Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cog-nitive impairment. Neurochem. Res. 32, 655-662. (Pubitemid 46481287)
84. Swatton, J.E., Sellers, L.A., Faull, R.L., Holland, A., Iritani, S., and Bahn, S. (2004). Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 19, 2711-2719. (Pubitemid 38746388)
85. Tandon, A., Yu, H., Wang, L., Rogaeva, E., Sato, C., Chishti, M.A., Kawarai, T., Hasegawa, H., Chen, F, Davies, P., et al. (2003). Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofi-brillary tangles. J. Neurochem. 86, 572-581. (Pubitemid 36897438)
86. Taniguchi, S., Fujita, Y, Hayashi, S., Kakita, A., Takahashi, H., Murayama, S., Saido, T.C., Hisanaga, S., Iwatsubo, T., and Hasegawa, M. (2001). Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett. 489, 46-50. (Pubitemid 32176003)
87. Terry, R.D., Masliah, E., Salmon, D.P, Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., and Katzman, R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580.
88. Tseng, H.C., Zhou, Y, Shen, Y, and Tsai, L.H. (2002). A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523, 58-62. (Pubitemid 34786058)
89. Van den Haute, C., Spittaels, K., Van Dorpe, J., Lasrado, R., Vandezande, K., Laenen, I., Geerts, H., and Van Leuven, F (2001). Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice. Neurobiol. Dis. 8, 32-44. (Pubitemid 32171816)
90. Verma, I.M. and Weitzman, M.D. (2005). Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74, 711-738. (Pubitemid 40995522)
91. Wang, F, Corbett, D., Osuga, H., Osuga, S., Ikeda, J.E., Slack, R.S., Hogan, MJ., Hakim, A.M., and Park, D.S. (2002). Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat. J. Cereb. Blood Flow Metab. 22, 171-182. (Pubitemid 34135648)
92. Wang, J., Liu, S., Fu, Y, Wang, J.H., and Lu, Y (2003). Cdk5 activa-tion induces hippocampal CA1 cell death by directly phosphory-lating NMDA receptors. Nat. Neurosci. 6, 1039-1047. (Pubitemid 37186195)
93. Wei, FY, Tomizawa, K., Ohshima, T., Asada, A., Saito, T., Nguyen, C, Bibb, J.A., Ishiguro, K., Kulkarni, A.B., Pant, HC, et al. (2005). Control of cyclin-dependent kinase 5 (Cdk5) activity by glutamatergic regulation of p35 stability. J. Neurochem. 93, 502-512. (Pubitemid 40547507)
94. Wen, Y, Yang, S.H., Liu, R., Perez, EJ., Brun-Zinkernagel, A.M., Koulen, P., and Simpkins, J.W. (2007). Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473-483. (Pubitemid 46400382)
95. Wen, Y, Yu, WH., Maloney, B., Bailey, J., Ma, J., Marie, I., Maurin, T., Wang, L., Figueroa, H., Herman, M., et al. (2008a). Transcriptional regulation of β-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron 57, 680-690. (Pubitemid 351335351)
96. Wen, Y, Planel, E., Herman, M., Figueroa, H.Y, Wang, L., Liu, L., Lau, L.F, Yu, WH., and Duff, K.E. (2008b). Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28, 2624-2632. (Pubitemid 351348188)
97. Wolff, J.A. and Budker, V. (2005). The mechanism of naked DNA uptake and expression. Adv. Genet. 54, 3-20.
98. Wong, L.F, Goodhead, L., Prat, C, Mitrophanous, K.A., Kingsman, S.M., and Mazarakis, N.D. (2006). Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum. Gene Ther. 17, 1-9. (Pubitemid 43102718)
99. Xia, H, Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M., and Davidson, B.L. (2004). RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10, 816-820. (Pubitemid 39070854)
100. Yoo, B.C. and Lubec, G (2001). p25 protein in neurodegeneration. Nature 411, 763-764; discussion 764-765.
101. Zhang, M., Li, J., Chakrabarty, P., Bu, B., and Vincent, I. (2004). Cyclin-dependent kinase inhibitors attenuate protein hyperphos-phorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. Am. J. Pathol. 165, 843-853. (Pubitemid 39129292)
102. Zukerberg, L.R., Patrick, GN., Nikolic, M., Humbert, S., Wu, C.L., Lanier, L.M., Gertler, FB., Vidal, M., Van Etten, R.A., and Tsai, L.H. (2000). Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite out-growth. Neuron 26, 633-646.